{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T16:27:14Z","timestamp":1776270434405,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T00:00:00Z","timestamp":1512604800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40264-017-0623-1","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T11:09:13Z","timestamp":1512644953000},"page":"429-440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials"],"prefix":"10.1007","volume":"41","author":[{"given":"Dao","family":"Thai-Cuarto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher F.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace S.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,7]]},"reference":[{"key":"623_CR1","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.ijcard.2013.08.129","volume":"169","author":"P Carter","year":"2013","unstructured":"Carter P, Mann J, Sangha J, et al. The burden of cardiovascular disease amongst psychiatric patients. Int J Cardiol. 2013;169:e65\u20136.","journal-title":"Int J Cardiol"},{"key":"623_CR2","first-page":"552","volume":"28","author":"D Ames","year":"2002","unstructured":"Ames D, Camm J, Cook P, et al. Minimizing the risks associated with QTc prolongation in people with schizophrenia: a consensus statement by the Cardiac Safety in Schizophrenia Group. Encephale. 2002;28:552\u201362.","journal-title":"Encephale"},{"key":"623_CR3","doi-asserted-by":"crossref","first-page":"791017","DOI":"10.1155\/2009\/791017","volume":"2009","author":"BA Larsen","year":"2009","unstructured":"Larsen BA, Christenfeld NJS. Cardiovascular disease and psychiatric comorbidity: the potential role of perseverative cognition. Cardiovasc Psychiatry Neurol. 2009;2009:791017.","journal-title":"Cardiovasc Psychiatry Neurol"},{"key":"623_CR4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1359786810382468","volume":"24","author":"CJ Bushe","year":"2010","unstructured":"Bushe CJ, Taylor M, Haukka J. Mortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol. 2010;24:17\u201325.","journal-title":"J Psychopharmacol"},{"key":"623_CR5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0006-3223(03)00639-5","volume":"54","author":"DL Evans","year":"2003","unstructured":"Evans DL, Charney DS. Mood disorders and medical illness: a major public health problem. Biol Psychiatry. 2003;54:177\u201380.","journal-title":"Biol Psychiatry"},{"key":"623_CR6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","volume":"8","author":"M Hert De","year":"2012","unstructured":"De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8:114\u201326.","journal-title":"Nat Rev Endocrinol"},{"key":"623_CR7","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.2174\/1381612043383872","volume":"10","author":"P Pacher","year":"2004","unstructured":"Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des. 2004;10:2463\u201375.","journal-title":"Curr Pharm Des"},{"key":"623_CR8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00006842-198011000-00002","volume":"42","author":"RB Williams Jr","year":"1980","unstructured":"Williams RB Jr, Haney TL, Lee KL, et al. Type A behavior, hostility, and coronary atherosclerosis. Psychosom Med. 1980;42:539\u201349.","journal-title":"Psychosom Med"},{"key":"623_CR9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0749-3797(02)00439-7","volume":"23","author":"R Rugulies","year":"2002","unstructured":"Rugulies R. Depression as a predictor for coronary heart disease. a review and meta-analysis. Am J Prev Med. 2002;23:51\u201361.","journal-title":"Am J Prev Med"},{"key":"623_CR10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1517\/14740338.2013.840583","volume":"13","author":"CU Pae","year":"2014","unstructured":"Pae CU, Wang SM, Lee SJ, et al. Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram. Expert Opin Drug Saf. 2014;13:197\u2013205.","journal-title":"Expert Opin Drug Saf"},{"key":"623_CR11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/2042098612454283","volume":"3","author":"S Nachimuthu","year":"2012","unstructured":"Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf. 2012;3:241\u201353.","journal-title":"Ther Adv Drug Saf"},{"key":"623_CR12","unstructured":"FDA approves first drug to treat tardive dyskinesia [press release]. Silver Spring: US Food and Drug Administration; 2017."},{"key":"623_CR13","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s13311-013-0222-5","volume":"11","author":"LJ Cloud","year":"2014","unstructured":"Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11:166\u201376.","journal-title":"Neurotherapeutics"},{"key":"623_CR14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5334\/tohm.199","volume":"4","author":"D Zutshi","year":"2014","unstructured":"Zutshi D, Cloud LJ, Factor SA. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic. Tremor Other Hyperkinet Mov (N Y). 2014;4:266.","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"623_CR15","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2147\/DDDT.S32328","volume":"7","author":"AQ Rana","year":"2013","unstructured":"Rana AQ, Chaudry ZM, Blanchet PJ. New and emerging treatments for symptomatic tardive dyskinesia. Drug Des Dev Ther. 2013;7:1329\u201340.","journal-title":"Drug Des Dev Ther"},{"key":"623_CR16","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/mds.26330","volume":"30","author":"CF O\u2019Brien","year":"2015","unstructured":"O\u2019Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015;30:1681\u20137.","journal-title":"Mov Disord"},{"key":"623_CR17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","volume":"174","author":"RA Hauser","year":"2017","unstructured":"Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476\u201384.","journal-title":"Am J Psychiatry"},{"key":"623_CR18","doi-asserted-by":"publisher","unstructured":"Factor SA, Remington G, Comella CL, et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study. J Clin Psychiatry. 2017. https:\/\/doi.org\/10.4088\/JCP.17m11777 (Epub ahead of print).","DOI":"10.4088\/JCP.17m11777"},{"key":"623_CR19","unstructured":"Ingrezza [prescribing information]. San Diego: Neurocrine Biosciences, Inc.; 2017."},{"issue":"Suppl. 1","key":"623_CR20","first-page":"S304","volume":"29","author":"R Jimenez","year":"2014","unstructured":"Jimenez R, Shiwach R, Bari M, O\u2019Brien CF. 12-week treatment of tardive dyskinesia with NBI-98854 [poster no. 826]. Mov Disord. 2014;29(Suppl. 1):S304.","journal-title":"Mov Disord"},{"key":"623_CR21","unstructured":"Combined list of drugs that prolong QT and\/or cause torsades de pointes (TDP). Updated October 2017. http:\/\/crediblemeds.org\/pdftemp\/pdf\/CombinedList.pdf . Accessed 8 Nov 2017."},{"key":"623_CR22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4172\/2167-1095.1000104","volume":"1","author":"V Milazzo","year":"2012","unstructured":"Milazzo V, Stefano CD, Servo S, et al. Drugs and orthostatic hypotension: evidence from literature. J Hypertens. 2012;1:104.","journal-title":"J Hypertens"},{"key":"623_CR23","unstructured":"Xenazine [prescribing information]. Deerfield: Lundbeck; 2015."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-017-0623-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0623-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0623-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T23:32:21Z","timestamp":1603495941000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-017-0623-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,7]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["623"],"URL":"https:\/\/doi.org\/10.1007\/s40264-017-0623-1","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,7]]}}}